Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 299Carboplatin 229Cisplatin 159Gemcitabine 152Paclitaxel 151Pemetrexed 121Bevacizumab 121Docetaxel 106Oxaliplatin 82durvalumab 81Nivolumab 81Dexamethasone 80atezolizumab 79Fluorouracil 79Cyclophosphamide 77130-nm albumin-bound paclitaxel 73Fulvestrant 72Capecitabine 67Injections 66Cetuximab 64Leucovorin 63Rituximab 56fludarabine 51Lenalidomide 50venetoclax 46Prednisone 45Letrozole 42Irinotecan 42enzalutamide 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × romiplostim × 90 days × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡